<p>Ratings for Chemours (NYSE:CC) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.4, a high estimate of $21.00, and a low estimate of $13.00. Experiencing a 7.45% decline, the current average is now lower than the previous average price target of $18.80. </p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769000466_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="price target chart" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769000466_0.png"/></p>

<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A comprehensive examination of how financial experts perceive Chemours is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Chemours. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Chemours compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Chemours's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Chemours's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p>Stay up to date on Chemours analyst ratings.</p>
<h2>Delving into Chemours's Background</h2>
<p>The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal &amp; Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.</p>
<h3>Chemours: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Chemours faced challenges, resulting in a decline of approximately <strong>-0.86%</strong> in revenue growth as of 30 September, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Chemours's net margin is impressive, surpassing industry averages. With a net margin of <strong>4.01%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Chemours's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>22.43%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Chemours's ROA excels beyond industry benchmarks, reaching <strong>0.8%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Chemours's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>14.82</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>

<p>Chemours (NYSE:CC) received mixed ratings from 5 analysts over the past three months, with an average 12-month price target of $17.4, down from $18.8. Recent evaluations show a range of bullish to bearish sentiments. Key analysts include Peter Osterland (Truist Securities) raising his target to $21.00, while Jeffrey Zekauskas (JP Morgan) lowered his to $13.00. Chemours has faced a revenue decline of approximately -0.86% and has a strong net margin of 4.01% and ROE of 22.43%, but a high debt-to-equity ratio of 14.82 raises concerns about financial leverage.</p>

A Glimpse Into The Expert Outlook On Chemours Through 5 Analysts